Antithrombotic Therapy Not Warranted in COVID-19 Outpatients Antithrombotic Therapy Not Warranted in COVID-19 Outpatients

In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI, stroke, or hospitalization in the ACTIV-4B trial.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news

Related Links:

Background: The Covid 19 pandemic has a vast socioeconomic impact worldwide. Obtaining information about the course of the disease is vital for better management.Aim: To assess the risk, comorbidities (CMs) and mortality in hospitalized patients with Covid 19 pneumonia.Methods: The information was gathered from the medical registry and statistical analysis was performed using SPSS.Results: A total of 337 patient were analyzed. Males were 197 (58,5%). Positive PCR results had 307 (91,1%) patients. Almost half of the patients were with respiratory failure on admission (47,1%). At least one comorbidity was found in 84,6%. Fro...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections and bronchiectasis Source Type: research
Coronavirus disease 2019 (COVID-19) can lead to systemic coagulation activation and thrombotic complications(TC), which may lead to fatal outcomes if not diagnosed and managed appropriately.We aimed to report the incidence and characteristics of venous and arterial thrombotic complications(TC) in hospitalized patients with COVID-19 and to investigate the predictive factors of their occurrence.A retrospective study including 200 patients with COVID-19 confirmed by a reverse transcription polymerase chain reaction test, admitted between March 2020 and January 2021 in the pulmonary departement B at Abderrahman Mami Hospi...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections and bronchiectasis Source Type: research
This study is a retrospective analysis of our PAH patients treated in 2020 compared to the dynamics of the last 12 years. We had 48 PAH patients, 51.72±16.64 years, 72.91% female. All patients had chronic anticoagulant therapy(58.33%) and/or antiplatelet; 33.33% had long term oxygen therapy. Three patients with secondary forms were confirmed with COVID-19, all hospitalized (6.25% infection rate versus 3.29% in general). One patient died(75 years with scleroderma, stroke), two patients were cured (mild forms). In total only three patients died in 2020. Surprisingly, compared with 2008-2019 (101 patients/ 41 deaths, 3...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pulmonary hypertension Source Type: research
Standard biomarkers have been widely used for COVID-19 diagnosis and prognosis. We hypothesize that thrombogenicity metrics measured by thromboelastography will provide better diagnostic and prognostic utility versus standard biomarkers in COVID-19 positive patients. In this observational prospective study, we included 119 hospitalized COVID-19 positive patients and 15 COVID-19 negative patients. On admission, we measured standard biomarkers and thrombogenicity using a novel thromboelastography assay (TEG-6s). In-hospital all-cause death and thrombotic occurrences (thromboembolism, myocardial infarction and stroke) were re...
Source: Blood Coagulation and Fibrinolysis - Category: Hematology Tags: ORIGINAL ARTICLES Source Type: research
Thromb Haemost. 2021 Nov 13. doi: 10.1055/s-0041-1739411. Online ahead of print.ABSTRACTThe consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practitioners in the Asia-Pacific region. In these years, many important new data regarding stroke prevention in AF were reported. The practice guidelines subcommittee members comprehensively reviewed updated information on stroke prevention in AF, and summarized them in this 2021 focused update of the...
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Source Type: research
In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as a virally transmitted disease. Three months later, SARS-CoV-2 became one of the largest pandemics in recent times, causing more than 235 million cases globally, and accounting for at least 4.8 million deaths to date. SARS-COV-2 infection was initially classified as a respiratory tract infection, but later was recognized as a multisystemic disease compromising gastrointestinal, hematological, cardiac, and neurological systems. With this Review, we aim to describe the epidemiology, risk factors, mechanisms, and management of cere...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Orv Hetil. 2021 Nov 7;162(45):1803-1807. doi: 10.1556/650.2021.32355.ABSTRACTÖsszefoglaló. A COVID-19 világméretű járvány kapcsán már jól ismertek az általános akut tünetek, mint a láz, a száraz köhögés, a nehézlégzés, a tüdőgyulladás, a hasi panaszok, a hasmenés, az ízérzés- és szaglásvesztés. Talán kevésbé ismertek a betegség neurológiai szövődményei: az encephalitis, a fejfá...
Source: Orvosi Hetilap - Category: General Medicine Authors: Source Type: research
AbstractCOVID-19 (Coronavirus disease 2019) caused by SARS-CoV-2 has a diverse constellation of neurological manifestations that include encephalopathy, stroke, Guillain –Barré syndrome, myelitis, and encephalitis. Intraluminal carotid thrombi (ILT) are infrequent lesions seen in only 1.6% of patients with acute ischemic stroke. Underlying atherosclerosis is the most common lesion associated with ILT formation. However, with COVID-19, we have encountered ILT in p atients without significant atherosclerotic disease. The endothelial inflammation and hypercoagulable state associated with COVID-19 pose a risk of a...
Source: Journal of Neurology - Category: Neurology Source Type: research
Patients on left ventricular assist device (LVAD) support may be susceptible to severe disease and complications from coronavirus disease-19 (COVID-19). The purpose of this study was to describe the clinical course of COVID-19 in LVAD patients. A retrospective review was performed at our center; 28 LVAD patients who developed COVID-19 between March 2020 and March 2021, and six patients with a prior COVID-19 infection who underwent LVAD implantation, were identified and examined. Of the 28 patients, nine (32%) died during the study period, five (18%) during their index hospitalization for COVID-19. Two patients (7%) present...
Source: ASAIO Journal - Category: Medical Devices Tags: Management of COVID-19 Patients Source Type: research
AbstractThe coronavirus disease 2019 (COVID-19) pandemic is an issue of global significance that has taken the lives of many across the world. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for its pathogenesis. The pulmonary manifestations of COVID-19 have been well described in the literature. Initially, it was thought to be limited to the respiratory system; however, we now recognize that COVID-19 also affects several other organs, including the nervous system. Two similar human coronaviruses (CoV) that cause severe acute respiratory syndrome (SARS-CoV-1) and Middle East respirator...
Source: Journal of Molecular Neuroscience - Category: Neuroscience Source Type: research
More News: Aspirin | Cardiology | COVID-19 | Heart | Stroke | Thrombosis